Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell Lymphoma

Video

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

Basem William, MD, MRCP, FACP, associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin (Adcetris) and lenalidomide (Revlimid) in patients with relapsed/refractory cutaneous and peripheral T-cell lymphomas.

This trial, modeled after a prior trial in diffuse large B-cell lymphoma, initially gave patients 1.2 mg/kg of brentuximab vedotin and 20 mg of lenalidomide, explains William. However, an excessive tumor flare in the skin was seen and the lenalidomide dose was dropped to 10 mg after treating 7 patients, says William.

Most patients in the trial had heavily pretreated cutaneous T-cell lymphoma with a median 5 lines of prior therapy. Additionally, there was no required CD30 positivity. The overall response rate was 33%, according to William. The preliminary results report on 17 patients and the ongoing study's goal is 32 patients, concluded William.

Related Videos
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
James Knight, MD
Vlad Gabriel Zaha, MD, PhD
Raj Singh, MD
Idalid Franco, MD, MPH